Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrSense launches noninvasive haemoglobin monitor for pregnant women

This article was originally published in Clinica

Executive Summary

OrSense has launched its NBM200, a noninvasive point-of-care haemoglobin monitor for the detection of anaemia and haemorrhage during pregnancy. The disorder is common in pregnant women because they require more iron. Anaemia increases the risk of low neonatal birth weight and maternal mortality. The device, which is based on OrSense's proprietary occlusion spectroscopy technology, uses a ring-shaped probe that fits on the finger, thereby avoiding conventional blood sampling. It is CE marked for sale in Europe and has been submitted for US FDA 510(k) clearance. Nes Ziona, Israel-based OrSense has also developed a multiparameter monitoring system, NBM-200MP, which received 510(k) clearance in March (www.clinica.co.uk, 24 March 2010).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel